News
-
-
PRESS RELEASE
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Sonnet BioTherapeutics Holdings, Inc. initiates review of strategic alternatives to maximize stockholder value with financial advisor Chardan Capital Markets. Evaluation may lead to various strategic transactions but no definitive decisions made yet -
-
PRESS RELEASE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics reports positive safety and efficacy data from Phase 1 clinical trials of SON-1010, a novel immunotherapeutic drug for solid tumors, demonstrating extended half-life and clinical benefit in patients -
-
PRESS RELEASE
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Sonnet BioTherapeutics announces financial results and corporate updates including Phase 1 data on SON-1010 safety, net proceeds from tax program, and clinical trial progress on SON-080 for CIPN -
-
-
-
PRESS RELEASE
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Sonnet BioTherapeutics to present preclinical data on SON-080 for neuropathies at AACR Annual Meeting 2024. The study focuses on safety and clinical plans using recombinant human Interleukin-6
![Accesswire](/assets/images/accesswire-inline.png)
-
Fresh Consulting Partners With Balanced Engineering to Propel Innovation in Autonomous Vehicles and Robotics for Nearshore OEMs and Global Suppliers
-
Ostrom Climate Announces Nature-Based Solutions Cooperation Agreement with Klima 1.5 Corp. In The Philippines
-
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
-
Kerr Introduces OptiBond Universal 360
-
NioCorp Announces Closing of Private Placement for Gross Proceeds of US$0.6 Million
![EQS Group](/assets/images/eqs-group.png)
-
Blue Cap AG: Annual General Meeting approves dividend of EUR 0.65 per share and appoints two new Supervisory Board members
-
EQS-Adhoc: Nakiki SE: Preliminary results for 2022 and 2023
-
Pyrum Innovations AG: Expansion of the use of Pyrum rCB in the Schwalbe tyre product range
-
Biotest's sustainability campaign GoFuture part of the new documentary 'Future Seeds'
-
Schweizer Electronic AG (SCHWEIZER) and Zollner Elektronik AG (Zollner) announce strategic partnership in the field of power embedding
![Les Echos](/assets/images/les-echos.png)
-
GUILLEMOT CORPORATION: Weekly report share buyback from June 17th 2024 to June 21st 2024
-
Statement of transactions in own shares from June 17, 2024 to June 19, 2024
-
Safran: exclusive discussions to acquire Preligens
-
PR – ICADE – Alexis de Nervaux is named Head of IT and Digital Transformation and joins Icade’s Executive Committee
-
Annual Results for 2023/2024